Strong sales of immunoassay systems for Fujirebio
First written in FY2018-Q1. 4 of 6 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2019: 3 of 9 companies on the "Worse" side.
1 other company's latest entry also says "Dropped".
- FY2023DroppedAnnual reportThe current securities report contains no reference to the previously reported strong sales of immunoassay systems for Fujirebio.
- FY2019RestatedAnnual report
「Our products continue to have a competitive advantage due to their low reagent and specimen usage and their advantage in running costs. Sales of biochemical automated analyzers for the domestic market and immunoassay systems supplied to Fujirebio as an OEM customer remained strong.」
The advantages of the medical equipment business in reagent and specimen usage and running costs, as well as strong sales in Japan and to Fujirebio, have continued. - FY2018RestatedAnnual report
「Sales of biochemical automated analyzers for the domestic market and immunoassay systems supplied to Fujirebio as an OEM customer remained strong.」
Strong sales of biochemical automated analyzers for the domestic market and immunoassay systems for Fujirebio have been reiterated in the full-year report. - FY2018-Q3RestatedAnnual report
「Sales of biochemical automated analyzers for the domestic market and immunoassay systems supplied to Fujirebio as an OEM customer remained strong.」
Strong sales of biochemical automated analyzers for the domestic market and immunoassay systems for Fujirebio have been reiterated. - FY2018-Q2RestatedAnnual report
「Sales of biochemical automated analyzers for the domestic market and immunoassay systems supplied to Fujirebio as an OEM customer remained strong.」
Strong sales of biochemical automated analyzers for the domestic market and immunoassay systems for Fujirebio have been reiterated. - FY2018-Q1First statedAnnual report
「Sales of biochemical automated analyzers for the domestic market and immunoassay systems supplied to Fujirebio as an OEM customer remained strong.」
The medical equipment business records, for the first time, strong sales of biochemical automated analyzers for the domestic market and immunoassay systems supplied to Fujirebio.